Ipamorelin
Growth Hormone Secretagogues
£28.00per vial
Awaiting batch
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
Ipamorelin cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Ipamorelin is a research peptide listed in the UK for in-vitro laboratory use only. It is not a medicine and it is not for human or veterinary use. This page is the Ipamorelin listing for Protocol Peptides UK.
Ipamorelin is a synthetic pentapeptide and a selective agonist at the growth hormone secretagogue receptor GHSR-1a, the ghrelin receptor. Laboratory work uses it to examine growth hormone pulsatility and ghrelin-receptor biology, where its selectivity profile separates it from broader-spectrum secretagogues.
Also known as NNC 26-0161.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
- UK DISPATCH
- TRACKED SHIPPING
- COA ON RELEASE
- SECURE PAYMENT
Compound details
Ipamorelin is a synthetic pentapeptide and a selective agonist at the growth hormone secretagogue receptor GHSR-1a, the ghrelin receptor. Laboratory work uses it to examine growth hormone pulsatility and ghrelin-receptor biology, where its selectivity profile separates it from broader-spectrum secretagogues.
Ipamorelin is a synthetic pentapeptide studied in controlled laboratory settings for its activity at the growth hormone secretagogue receptor GHSR-1a, the receptor natively bound by ghrelin. It is a G-protein coupled receptor agonist, and receptor engagement is examined through the phospholipase C and inositol trisphosphate second-messenger route characteristic of that receptor class.
- Molecular weight
- 711.9 g/mol
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Presentation
- Sealed 3ml vial
Molecular weight source: PubChem CID 9831659. View the PubChem record
Ipamorelin is a synthetic pentapeptide studied in controlled laboratory settings for its activity at the growth hormone secretagogue receptor GHSR-1a, the receptor natively bound by ghrelin. It is a G-protein coupled receptor agonist, and receptor engagement is examined through the phospholipase C and inositol trisphosphate second-messenger route characteristic of that receptor class.
The research interest in Ipamorelin is its selectivity. Earlier growth hormone releasing peptides such as GHRP-6 and GHRP-2 show measurable cross-activity at corticotroph and lactotroph pathways in the same models. Ipamorelin is examined specifically because that cross-activity is markedly lower, which makes it useful as an isolating tool in study designs where GHSR-1a activity needs to be separated from broader pituitary signalling.
Preclinical investigations examine Ipamorelin in hypothalamic-pituitary axis models, in ghrelin-receptor binding characterisation, and in bone and gastric motility research frameworks. It is catalogued here as a reference compound for laboratory research. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Ipamorelin is listed in a sealed 3ml vial, at 5mg and 10mg.
When a batch is released, it is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
When a batch is released, the batch number on the vial resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date. The document is published before the batch enters the catalogue, not issued on request afterwards. Specimen documents on this site are for demonstration only and are not genuine laboratory reports.
When a batch is released, it is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
Ipamorelin
IP5604Specimen record. Not a genuine laboratory report.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 99.1% |
| Identity | Mass spectrometry | Consistent with expected mass |
HPLC
Purity by chromatography
ON RELEASE
MASS SPECTROMETRY
Identity confirmation
ON RELEASE
PUBLIC COA
Each released batch number resolves to its Certificate of Analysis
COMMITTED
Research Use Only
Ipamorelin is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Ipamorelin. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
When analytical results are published for Ipamorelin, they relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch. Specimen documents are for demonstration only and are not genuine laboratory reports.
Jurisdiction Notice
Ipamorelin cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Every released batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number then resolves to the report. Specimen documents on this site are for demonstration only.
For laboratory research only. Not for human consumption. No medical claims.
